Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Fineline Cube Sep 8, 2026
Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Fineline Cube Sep 8, 2026
Company Medical Device

J&J MedTech Launches Locally Produced HARMONIC 7s Scalpel in China

Fineline Cube Feb 26, 2025

Johnson & Johnson MedTech, a US-based healthcare giant, announced the official launch of its HARMONIC...

Company Deals

Thermo Fisher to Acquire Solventum’s Purification Business for USD 4.1B

Fineline Cube Feb 26, 2025

Thermo Fisher Scientific (NYSE: TMO) has agreed to acquire Solventum’s (NYSE: SOLV) Purification & Filtration...

Company Drug

J&J’s Tremfya Wins NMPA Approval for Crohn’s Disease Treatment

Fineline Cube Feb 26, 2025

Johnson & Johnson (J&J, NYSE: JNJ) announced that its Tremfya (guselkumab) has received marketing approval...

Company Drug

Sanofi’s Sarclisa Wins New Japan Approval for Multiple Myeloma Combination Therapy

Fineline Cube Feb 26, 2025

Sanofi (EPA: SAN, NASDAQ: SNY) announced that Japan’s Ministry of Health, Labour and Welfare (MHLW)...

Company Drug

YolTech Therapeutics’ YOLT-203 Shows Promise in Primary Hyperoxaluria Type 1 Trial

Fineline Cube Feb 26, 2025

YolTech Therapeutics, a Shanghai-based startup specializing in lipid nanoparticle delivery and gene editing, announced positive...

Company Deals

HQ Pharma and Shanghai Pharmaceuticals Expand Collaboration for Global Market Access

Fineline Cube Feb 26, 2025

China’s HQ Pharma (Shanghai) Co., Ltd has entered into a new collaboration agreement with Shanghai...

Company Deals

Green Valley and Vazyme Team Up on Alzheimer’s Disease Initiatives

Fineline Cube Feb 26, 2025

China-based Green Valley (Shanghai) Pharmaceuticals Co., Ltd. and Vazyme Biotech Co., Ltd (SHA: 688105) have...

Company Drug

Merck’s Keytruda sBLA for LA-HNSCC Accepted by FDA for Review

Fineline Cube Feb 26, 2025

Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) announced that the US Food and Drug...

Company Deals

CARsgen Therapeutics and Zhuhai SB Xinchuang Invest in UCARsgen for Allogeneic CAR-T Therapies

Fineline Cube Feb 26, 2025

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has entered into an agreement with an investment...

Company Drug

Eli Lilly Launches New Zepbound Doses with Lower Prices for Self-Pay Patients

Fineline Cube Feb 26, 2025

Eli Lilly & Co. (NYSE: LLY) announced the launch of 7.5 mg and 10 mg...

Company Drug

Suzhou Ribo Life Science’s RBD2080 siRNA Drug Receives Australian Clinical Trial Approval

Fineline Cube Feb 26, 2025

China-based Suzhou Ribo Life Science Co., Ltd announced that its siRNA drug RBD2080 has received...

Company

MicuRx Pharmaceuticals Sues Medpace Over Breach of Contract in Phase III Study

Fineline Cube Feb 26, 2025

Sino-US biotech firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has filed a lawsuit against US-based Medpace,...

Company Deals

Eli Lilly Acquires Organovo’s FXR Program for Inflammatory Bowel Disease

Fineline Cube Feb 26, 2025

US-based Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical-stage biotech focused on inflammatory bowel disease (IBD),...

Company Medical Device

Acotec Scientific’s Vericor Catheter Wins NMPA Approval for Peripheral Vascular Surgery

Fineline Cube Feb 25, 2025

China-based Acotec Scientific Holdings Ltd (HKG: 6669) announced that its peripheral disposable support catheter Vericor...

Drug

CANbridge Pharmaceuticals Doses First Patient in CAN108 Biliary Atresia Study

Fineline Cube Feb 25, 2025

China-based rare disease specialist CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that the first patient has...

Company Drug

Sandoz Launches Pyzchiva Biosimilar of J&J’s Stelara in US

Fineline Cube Feb 25, 2025

Switzerland-based Sandoz (SWX: SDZ) announced the launch of Pyzchiva, a biosimilar version of Johnson &...

Company

CDE Includes Chiral Tech’s Cerdelga Generic in Rare Disease Care Plan

Fineline Cube Feb 25, 2025

China’s Center for Drug Evaluation (CDE) announced the inclusion of Beijing Chiral Tech’s generic version...

Company Medical Device

Medtronic’s BrainSense Adaptive DBS Wins FDA Approval for Parkinson’s Treatment

Fineline Cube Feb 25, 2025

US-Irish medical device giant Medtronic (NYSE: MDT) announced that the US Food and Drug Administration...

Legal / IP

SMPA Suspends Indobufen Procurement After Patent Infringement Verdict

Fineline Cube Feb 25, 2025

Shanghai’s Sunshine Medical Procurement All-In-One (SMPA) announced the suspension of procurement for indobufen, manufactured by...

Company Drug

Xellsmart’s iPSC Therapy XS-228 Receives FDA Approval for ALS Study

Fineline Cube Feb 25, 2025

Suzhou-based stem-cell startup Xellsmart announced that the U.S. FDA has approved its regulatory study of...

Posts pagination

1 … 258 259 260 … 718

Recent updates

  • Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections
  • China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback
  • Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation
  • CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally
  • Insilico Medicine Partners with Byterna Therapeutics to Build Next‑Generation mRNA AI‑Native R&D Engine – Targeting Circular mRNA Personalized Cancer Vaccines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Company Deals

Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation

Company Deals

CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.